Zimlovisertib
As of the edition of 20 October 2026, Zimlovisertib is a small molecule: stopped in 2021; acts on IRAK4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 11, 1 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IRAK4 | Interleukin-1 receptor-associated kinase 4 | Q9NWZ3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2014 to now |